ACHV Quote, Financials, Valuation and Earnings

Hear AtLast Holdings, Inc. has a net margin of -- compared to Achieve Life Sciences, Inc.'s net margin of --. Achieve Life Sciences, Inc.'s return on equity of -189.88% beat Hear AtLast Holdings, Inc.'s return on equity of --.

Achieve Life Sciences, Inc. has a consensus price target of $15.38, signalling upside risk potential of 251.83%. On the other hand Hear AtLast Holdings, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Achieve Life Sciences, Inc. has higher upside potential than Hear AtLast Holdings, Inc., analysts believe Achieve Life Sciences, Inc. is more attractive than Hear AtLast Holdings, Inc..

Achieve Life Sciences, Inc. has a beta of 1.819, which suggesting that the stock is 81.923% more volatile than S&P 500. In comparison Hear AtLast Holdings, Inc. has a beta of 0.388, suggesting its less volatile than the S&P 500 by 61.2%.

Achieve Life Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hear AtLast Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Achieve Life Sciences, Inc. pays -- of its earnings as a dividend. Hear AtLast Holdings, Inc. pays out -- of its earnings as a dividend.

Achieve Life Sciences, Inc. quarterly revenues are --, which are smaller than Hear AtLast Holdings, Inc. quarterly revenues of --. Achieve Life Sciences, Inc.'s net income of -$14.4M is lower than Hear AtLast Holdings, Inc.'s net income of -$152.6K. Notably, Achieve Life Sciences, Inc.'s price-to-earnings ratio is -- while Hear AtLast Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Achieve Life Sciences, Inc. is -- versus -- for Hear AtLast Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Oncolytics Biotech, Inc. has a net margin of -- compared to Achieve Life Sciences, Inc.'s net margin of --. Achieve Life Sciences, Inc.'s return on equity of -189.88% beat Oncolytics Biotech, Inc.'s return on equity of -635.07%.

Achieve Life Sciences, Inc. has a consensus price target of $15.38, signalling upside risk potential of 251.83%. On the other hand Oncolytics Biotech, Inc. has an analysts' consensus of $10.30 which suggests that it could grow by 456.5%. Given that Oncolytics Biotech, Inc. has higher upside potential than Achieve Life Sciences, Inc., analysts believe Oncolytics Biotech, Inc. is more attractive than Achieve Life Sciences, Inc..

Achieve Life Sciences, Inc. has a beta of 1.819, which suggesting that the stock is 81.923% more volatile than S&P 500. In comparison Oncolytics Biotech, Inc. has a beta of 0.988, suggesting its less volatile than the S&P 500 by 1.202%.

Achieve Life Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oncolytics Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Achieve Life Sciences, Inc. pays -- of its earnings as a dividend. Oncolytics Biotech, Inc. pays out -- of its earnings as a dividend.

Achieve Life Sciences, Inc. quarterly revenues are --, which are smaller than Oncolytics Biotech, Inc. quarterly revenues of --. Achieve Life Sciences, Inc.'s net income of -$14.4M is lower than Oncolytics Biotech, Inc.'s net income of -$10.5M. Notably, Achieve Life Sciences, Inc.'s price-to-earnings ratio is -- while Oncolytics Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Achieve Life Sciences, Inc. is -- versus -- for Oncolytics Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

StimCell Energetics, Inc. has a net margin of -- compared to Achieve Life Sciences, Inc.'s net margin of --. Achieve Life Sciences, Inc.'s return on equity of -189.88% beat StimCell Energetics, Inc.'s return on equity of --.

Achieve Life Sciences, Inc. has a consensus price target of $15.38, signalling upside risk potential of 251.83%. On the other hand StimCell Energetics, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Achieve Life Sciences, Inc. has higher upside potential than StimCell Energetics, Inc., analysts believe Achieve Life Sciences, Inc. is more attractive than StimCell Energetics, Inc..

Achieve Life Sciences, Inc. has a beta of 1.819, which suggesting that the stock is 81.923% more volatile than S&P 500. In comparison StimCell Energetics, Inc. has a beta of 48.964, suggesting its more volatile than the S&P 500 by 4796.448%.

Achieve Life Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. StimCell Energetics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Achieve Life Sciences, Inc. pays -- of its earnings as a dividend. StimCell Energetics, Inc. pays out -- of its earnings as a dividend.

Achieve Life Sciences, Inc. quarterly revenues are --, which are smaller than StimCell Energetics, Inc. quarterly revenues of --. Achieve Life Sciences, Inc.'s net income of -$14.4M is lower than StimCell Energetics, Inc.'s net income of -$309.7K. Notably, Achieve Life Sciences, Inc.'s price-to-earnings ratio is -- while StimCell Energetics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Achieve Life Sciences, Inc. is -- versus 1,937.12x for StimCell Energetics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Venus Concept, Inc. has a net margin of -- compared to Achieve Life Sciences, Inc.'s net margin of -163.68%. Achieve Life Sciences, Inc.'s return on equity of -189.88% beat Venus Concept, Inc.'s return on equity of -1236.95%.

Achieve Life Sciences, Inc. has a consensus price target of $15.38, signalling upside risk potential of 251.83%. On the other hand Venus Concept, Inc. has an analysts' consensus of -- which suggests that it could grow by 31413.51%. Given that Venus Concept, Inc. has higher upside potential than Achieve Life Sciences, Inc., analysts believe Venus Concept, Inc. is more attractive than Achieve Life Sciences, Inc..

Achieve Life Sciences, Inc. has a beta of 1.819, which suggesting that the stock is 81.923% more volatile than S&P 500. In comparison Venus Concept, Inc. has a beta of -0.011, suggesting its less volatile than the S&P 500 by 101.098%.

Achieve Life Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Venus Concept, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Achieve Life Sciences, Inc. pays -- of its earnings as a dividend. Venus Concept, Inc. pays out -- of its earnings as a dividend.

Achieve Life Sciences, Inc. quarterly revenues are --, which are smaller than Venus Concept, Inc. quarterly revenues of $13.8M. Achieve Life Sciences, Inc.'s net income of -$14.4M is higher than Venus Concept, Inc.'s net income of -$22.5M. Notably, Achieve Life Sciences, Inc.'s price-to-earnings ratio is -- while Venus Concept, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Achieve Life Sciences, Inc. is -- versus 0.01x for Venus Concept, Inc.. Usually stocks with elevated PS ratios are considered overvalued.